AusCann (ASX: AC8) has announced the appointment of Mr Ido Kanyon as new CEO, commencing 22 May.
This follows Elaine Darby stepping down as Managing Director in September 2018.
Mr Kanyon has over 15 years in executive experience, most recently at Teva Pharmaceuticals, the world’s largest generic pharmaceutical company.
At Teva, Mr Kanyon served as their Global Head of Specialty Pipeline, Global Marketing and Portfolio, based in the US. In this role, Ido was responsible for a multi-billion dollar portfolio with the goal of maximising the company’s R&D investment on innovative medicines.
AusCann Chairman, Dr Mal Washer, said “Our extensive executive search generated an impressive field of candidates and Ido stood out for his leadership acumen and track record of commercial achievements throughout his career.
“Ido is very highly regarded in the pharmaceutical industry and having worked both for startups and one of the largest pharmaceutical firms worldwide, he understands AusCann’s start-up origins and where the firm is headed. We are confident that his experience, energy and drive will successfully lead AusCann into its next phase of growth as a pharmaceutical development, sales and marketing business.
Mr Kanyon added, “I am absolutely delighted to be appointed as AusCann’s CEO during this exciting time. Medicinal cannabis will have an ever-increasing presence in healthcare as a credible treatment for chronic pain and additional indications with unmet medical needs. I believe there is a unique opportunity to place patients, physicians and caregivers at the centre of our mission.”
Mr Kanyon will start on May 22 with a base salary of $420,000.